Case number 1:24-cv-00151
AbbVie Inc. v. Hetero Labs Limited et al > Documents
| Date Field | Doc. No. | Description (Pages) |
|---|---|---|
| Mar 5, 2024 | 11 | SO ORDERED, re (7 in 1:24-cv-00153-JLH, 194 in 1:22-cv-01423-JLH, 7 in 1:24-cv-00154-JLH, 10 in 1:24-cv-00151-JLH, 10 in 1:24-cv-00152-JLH) Stipulation and Order regarding Consolidation for all purposes. Signed by Judge Jennifer L. Hall on 3/5/2024. Associated Cases: 1:22-cv-01423-JLH, 1:24-cv-00151-JLH, 1:24-cv-00152-JLH, 1:24-cv-00153-JLH, 1:24-cv-00154-JLH(ceg) (Entered: 03/05/2024) (8) |
| Mar 5, 2024 | N/A | Case associated with lead case: Create association to 1:22-cv-01423-JLH. ALL FUTURE FILINGS SHALL BE MADE IN LEAD CASE NO. 1:22-cv-01423-JLH ONLY. (ceg) (Entered: 03/05/2024) (0) |
| Mar 1, 2024 | 10 | STIPULATION and [Proposed] Order Regarding Consolidation by AbbVie Inc., AbbVie Ltd., Neurocrine Biosciences, Inc.. (Dellinger, Megan) (Entered: 03/01/2024) (8) |
| Feb 28, 2024 | 7 | SUMMONS Returned Executed by AbbVie Inc..Hetero USA Inc. served on 2/23/2024, answer due 3/15/2024. (Tigan, Jeremy) (Entered: 02/28/2024) (2) |
| Feb 28, 2024 | 8 | SUMMONS Returned Executed by AbbVie Inc..Hetero Labs Limited served on 2/23/2024, answer due 3/15/2024. (Tigan, Jeremy) (Entered: 02/28/2024) (2) |
| Feb 28, 2024 | 9 | SUMMONS Returned Executed by AbbVie Inc..Hetero Labs Limited Unit-V served on 2/23/2024, answer due 3/15/2024. (Tigan, Jeremy) (Entered: 02/28/2024) (2) |
| Feb 23, 2024 | 6 | Summons Issued as to Hetero Labs Limited, Hetero Labs Limited Unit-V, and Hetero USA Inc. on 2/23/2024. (Attachments: # 1 Summons Issued Hetero Labs Limited, # 2 Summons Issued Hetero USA Inc.)(jfm) (Entered: 02/23/2024) (0) |
| Feb 7, 2024 | N/A | Case Assigned to Judge Jennifer L. Hall. Please include the initials of the Judge (JLH) after the case number on all documents filed. Associated Cases: 1:24-cv-00151-JLH, 1:24-cv-00152-JLH, 1:24-cv-00153-JLH, 1:24-cv-00154-JLH (rjb) (Entered: 02/07/2024) (0) |
| Feb 5, 2024 | 1 | COMPLAINT for PATENT INFRINGEMENT filed against Hetero Labs Limited, Hetero Labs Limited Unit-V, and Hetero USA Inc. ( Filing fee $ 405, receipt number ADEDC-4330975.) - filed by AbbVie Inc. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Civil Cover Sheet)(smg) (Entered: 02/06/2024) (0) |
| Feb 5, 2024 | 2 | Notice, Consent and Referral forms re: U.S. Magistrate Judge jurisdiction. (smg) (Entered: 02/06/2024) (3) |
| Feb 5, 2024 | 3 | Supplemental information for patent cases involving an Abbreviated New Drug Application (ANDA) - Date Patentee(s) Received Notice: N/A Date of Expiration of Patent: U.S. Patent No. 11,690,845: August 27, 2040; U.S. Patent No. 11,690,854: April 19, 2038.Thirty Month Stay Deadline: 1/23/2026. (smg) (Entered: 02/06/2024) (2) |
| Feb 5, 2024 | 4 | Report to the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 11,690,845 B2; 11,690,854 B2. (smg) (Entered: 02/06/2024) (1) |
| Feb 5, 2024 | 5 | Disclosure Statement pursuant to Rule 7.1: No Parents or Affiliates Listed filed by AbbVie Inc. (smg) (Entered: 02/06/2024) (1) |
| Feb 5, 2024 | N/A | No Summons Issued. (smg) (Entered: 02/06/2024) (0) |
